论文部分内容阅读
用国产尿激酶（UK）100万IU静脉溶栓治疗91例首次急性心肌梗塞（AMI）患者，观察其临床疗效、并发症及对凝血、纤溶系统的作用。结果发现：1．国产UK的血管再通率为59．3％，出血并发症发生率为13％．再灌注性心律失常发生率为45％．但无致命性的严重心律失常发生；2．溶栓对AMI左心室功能的改善及病死率的降低．依赖于梗塞相关动脉（IRA）的再通；3．UK静脉注射后凝血酶原时间（PT）、凝血酶时间（TT）明显延长、纤溶酶活性显著升高、纤维蛋白原抗原显著下降。提示，血浆已处于明显的溶解状态。研究结果表明国产UK是一种安全、有效的溶栓药物。
Ninety-one patients with AMI were treated with intravenous thrombolytic therapy of 1 000 000 IU of urokinase (UK). The clinical efficacy, complications and the effects on coagulation and fibrinolytic system were observed. The results showed that: 1. Domestic UK’s vascular recanalization rate was 59.3%, the incidence of bleeding complications was 13%. The incidence of reperfusion arrhythmias was 45%. But no fatal serious arrhythmia; 2. Thrombolysis on AMI improved left ventricular function and mortality decreased. Rely on infarct related artery (IRA) recanalization; 3. UK prothrombin time (PT), thrombin time (TT) was significantly prolonged, plasmin activity was significantly increased, fibrinogen antigen decreased significantly. Tip, plasma has been in a state of obvious dissolution. The results show that domestic UK is a safe and effective thrombolytic drugs.